Curasight is active in the pharmaceutical industry. The company specializes in research and development of various drug candidates. The product portfolio includes, for example, research and development within Positron Emission Tomography (PET) and related ancillary services. The business is operating with the largest presence within Scandinavia. Curasight is headquartered in Copenhagen.

Quotes for Curasight A/S

Right Now

+/-
0.32
%
4,34%
Latest
7.7
High
7.7
Low
6.7
Volume
13 358
Turnover (DKK)
91 997
Market Value (MDKK)
162,8
Time (Latest trade)

Board

CEO

  • Ulrich Krasilnikoff

Chairperson of the Board

  • Kirsten Drejer

Board

  • Andreas Kjær
  • Charlotte Vedel
  • Lars Trolle
  • Ulrich Krasilnikoff

News

Show More

News agencies

Show More

Analysis

Videos

Curasight - Providing answers for cancer patients

Largest Owners

Name Capital % Votes % Date
Andreas Kjær 30,24 30,24 2023-12-31
UK Curacap ApS 19,46 19,46 2024-06-14
Carsten Haagen Nielsen 12,11 12,11 2023-12-31
Jacob Madsen 4,57 4,57 2023-12-31
Lars Trolle 2,95 2,95 2023-12-31
Chr. Olesen Holding A/S 2,01 2,01 2024-06-14
Gerhard Dal 0,33 0,33 2024-06-14
Per Falholt 0,33 0,33 2023-12-31
Johan Stein 0,20 0,20 2024-06-14
Charlotte Vedel 0,20 0,20 2023-12-31
Holdings by Modular Finance AB. Compiled and processed data from various sources, including VP Securities, Morningstar and The Danish Financial Supervisory Authority (Finanstilsynet)

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2025-05-28 Årsstämma 2024

  • 2025-05-28 Delårsrapport 2025-Q1

  • 2025-08-28 Delårsrapport 2025-Q2

  • 2025-11-27 Delårsrapport 2025-Q3

Annual reports, prospectus etc.